

Author(s) retain the copyright of this article.

Full Length Research Paper

Seroprevalence of HBV infection among patients attending Okayama Friendship Rural Hospital, Bhaluka, Mymensingh

Monir Ahmed

Monir Ahmed, Lecturer, Institute of Health Technology, Mohakhali, Dhaka, Bangladesh. Email: monirahmed.bd@gmail.com

Accepted 24 August, 2021

Hepatitis B virus (HBV) infection is a serious public health problem in around the globe. Even though South Asia and Bangladesh have a moderate prevalence rate of Hepatitis B virus, we are in great risk due to population mobility and the modes of transmission of virus through various ways. Current magnitude of HBV infection at rural areas of Bangladesh is unknown, and could be on the increase due to urbanization and industrialization with a change in lifestyle. During the study period of between 2nd of October and 27th of November, 2015 at the Okayama Friendship Rural Hospital, Bhaluka, Mymensingh a total of 354 patients came for various reasons and out of them only 60 patients were included in the study. Out of these, 04 had positive hepatitis B surface antigen (HBsAg). The Seroprevalence of HBsAg was thus 6.6% among the patients attending Okayama Friendship Rural Hospital, Bhaluka, Mymensingh. In fine, this study has found that the seroprevalence of HBV infection among patients at Okayama Friendship Rural Hospital, Bhaluka, Mymensingh was 6.6%, which is of moderate intensity, and hence it is suggestive of the need to adopt the WHO recommendations in our set up.

Keywords: Seroprevalence, HBV infection.

INTRODUCTION

The World Health Organization (WHO) considers hepatitis B virus (HBV) to be second to tobacco among the carcinogens (WHO 2002). Hepatitis B infection is caused by HBV which is a DNA virus belonging to a family called *Hepadnaviridae* which can cause acute or chronic infection (Kasper et al., 2005). It is estimated that 2 billion people worldwide have been affected of which 350 million people have chronic infection, and 10% of these are in sub-Saharan Africa and East Asia (1, 3).

These chronically infected patients may develop complications of liver cirrhosis and hepatocellular carcinoma. The clinical manifestations of HBV infection in acute infection are either prodromal, or icteric and recovery (Kasper et al., 2005). After the incubation period which varies depending to the type of virus, patients clinically present with chills, headache, nausea, vomiting and may precede jaundice (Kasper et al., 2005; Cunninghan et al., 2005). The liver becomes tender and enlarged with a right upper guadrant pain.

Splenomegaly and adenopathy may also occur in 10% to 20% of cases (Kasper et al., 2005). The recovery to normality clinically and biochemically is a rule in Hepatitis A Virus (HAV) and in almost all HBV infections (Kasper et al., 2005; Hasslett et al., 1999). However, some do remain chronically infected especially with HBV and HCV and may progress to liver cirrhosis and, or to hepatocellular carcinoma (Kasper et al., 2005; Hasslett et al., 1999). Reported consequences of HBV infection in pregnancy include an increased likelihood of occurrence of pre-term delivery and low birth weight (Cunninghan et al., 2005). Furthermore, HBV infection has been reported to be associated with threatened preterm labour, antepartum haemorrhage as well as gestational diabetes mellitus (Tse et al., 2005).

Diagnosis of HBV infection is confirmed by demonstrating specific antibodies and/or antigen in serum of patients (WHO 2002). The most important laboratory test for diagnosis of HBV infection is HBsAg which is the first antigen to appear, and appears during the incubation period, the prodrome, as well as during acute disease (Kasper et al., 2005; Levinson 1998). It appears after infection and disappears after one to two months following jaundice. During convalescence it falls to undetectable levels and if it persists for more than 6 months then this indicates a carrier state and a risk for chronic hepatitis and hepatocellular carcinoma (10). Presence of HBsAg means that the patient is potentially infectious. Antibodies to HBsAg (Anti-HBs) replace HBsAg as the acute infection resolves, and this indicates immunity in almost 80% of cases after the acute infection (Cunninghan et al., 2005). This Anti-HBs also appears after HBV vaccination. Some lose these antibodies that are acquired after acute HBV infection and may become susceptible to disease HBV (Cunninghan et al., 2005).

During the window period, and when the HBsAg has disappeared and HBsAb has not yet appeared, Hepatitis B core antibody (HBcAb) is detectable and can be used for diagnosis.

Acute or chronic infection can be differentiated by the presence of Immunoglobulin M (IgM) to HBcAg in acute infection, and Immunoglobulin G (IgG) in chronic infection (Kasper et al., 2005). After the appearance of HBsAg in one or two weeks, the HBcAb starts to be detectable. Very rarely HBcAg will be detected since it is within the HBsAg.

Investigations to be done among patients with HBV infection include the demonstration of Hepatitis B e antigen (HBeAg) which arises during the incubation period, prodrome, acute and to certain patients with chronic phase. It is an important indicator of transmissibility and is replaced by HBeAb, whose presence indicate low transmissibility (10). DNA polymerase is detected during the incubation period and early in the disease, and is a more sensitive and quantitative test (for the detection of viral load), although it is very expensive as it needs PCR (Cunninghan et al., 2005). Estimation of serum transaminases could also be done, which typically rises from 400 to 4000U/L. Similarly, bilirubin also usually rises in clinical jaundice (Cunninghan et al., 2005).

METHODOLOGY

Study area

This study was conducted at the Okayama Friendship Rural Hospital, Bhaluka, Mymensingh which is managed by Prof. Dr. Aftabuddin (PhD-Japan, Post doc-France). The study is conducted on Fridays.

On an average 53 patients attended at the Okayama Friendship Rural Hospital, Bhaluka, Mymensingh during the study on each Friday, of whom 65% were male and 35% were female patients. Most of these patients would come for a consultation with some minor ailments.

Among the usual services provided at the Okayama Friendship Rural Hospital, Bhaluka, Mymensingh are health education given by Nurses and paramedics who record weights and blood pressure readings at each visit. These are done before the patient enters a Doctor's room. Routine blood tests are performed by Medical Technologists and Pathologist as recommended by the Doctors.

Study design

This was a Clinic based cross-sectional study.

Study population.

The study population was all general patients attending Okayama Friendship Rural Hospital, Bhaluka, Mymensingh.

Inclusion criteria

Patients attending antenatal Okayama Friendship Rural Hospital, Bhaluka, Mymensingh for the first time and consent.

Exclusion criteria

Patients who had prior history of Hepatitis B Vaccination and attending the clinic for the first visit and who didn't consent to the study.

Study Period

The study was conducted between 2nd of October and 28th of November, 2015.

Sample size

Sample size for this study was calculated using the formula for cross-sectional study. Based on the 2-8% prevalence of HBsAg infection in Bangladesh, 60 people from different age, sex, occupation and education level were included.

Sampling technique

Patients attending the Okayama Friendship Rural Hospital, Bhaluka, Mymensingh were asked for consent and then enrolled until the desired sample size was reached.

The Research Assistants and researcher did not want to interfere with the regular services received by the patients. Therefore, the patients coming from each of the doctor's consultation room were asked to participate in the study by the Research Assistant and the investigator.

Following their consent, each was interviewed individually and blood sample was taken. Research Assistant ensured that all the patients coming out of Doctor's rooms were appropriately directed for study inclusion. The research assistant or the researcher picked another patient after finishing the previous one. This continued until the end of Doctor's consultation at the clinic.

Data collection method

Patients who consented to participate were subjected to a face-to-face interview with the investigator/assistant whereby pre-test counseling was done, and then the questionnaire was filled in to obtain information on sociodemographic characteristics. After this a venipuncture was performed and blood collected in a vacutainer tube. Five mls of blood was collected for Hepatitis B serology.

A mark was put in the clinic card of all enrolled patients to avoid repeat inclusions during their subsequent visits.

Laboratory investigations

Serological testing for HBV was performed at Okayama Friendship Rural Hospital, Bhaluka, Mymensingh by Medical Technologists and Pathologist.

HBsAg detection

This was performed using Immuno-chromatographic tests strips (Bioline HBsAg strip). The presence or absence of HBsAg in the sample was determined by comparing the test bands produced. Samples with a control band and test band were considered positive for HBsAg.

Bioline HBsAg One Test: -The Bioline HBsAg One Test qualitative, solid phase, two-site sandwich is a immunoassay for the detection of HBsAg in serum or plasma. The membrane is pre-coated with anti-HBsAg antibodies on the test band region and anti-mouse antibodies on the control band region. During testing, the serum sample reacts with the dye conjugate (mouse anti-HBsAg antibody colloidal gold conjugate) that has been coated in the test strip. The mixture then by capillary action, reacts with anti-HBsAg antibodies on the membrane and generates a red band. Presence of this red band indicates a positive result while its absence indicates a negative result. Regardless of the presence of HBsAg, as the mixture continues to migrate across the membrane to the immobilized goat anti-mouse region a red band at the control band region will always appear. The presence of this red band serves as verification for sufficient sample volume and proper flow and as a control for the reagents.

RESULTS

During the study period of between 2nd of October and 28th of November, 2015 at the Okayama Friendship Rural Hospital, Bhaluka, Mymensingh a total of 354 patients came for various reasons and out of them only 60 patients were included in the study. Out of these, 04 had positive hepatitis B surface antigen (HBsAg). The Seroprevalence of HBsAg was thus 6.6% among the patients attending Okayama Friendship Rural Hospital, Bhaluka, Mymensingh.

Seroprevalence of HBsAg was significantly higher among middle age and male patients with respect to age and sex. Also unemployed patients showed higher seroprevalence compared to other occupations. Another

Table 1. Baseline characteristics of patients who were enrolled in the study. According to their Age (N=60)

Characteristics	Total	HBsAg +ve n(%)	HBsAg -ve n(%)	Seroprevalence	
Age (years)					
Below 18	20	01 (5%)	19 (95%)	5%	
18-30	20	01 (5%)	19 (95%)	5%	
31 and more	20	02 (10%)	18 (90%)	10%	

Table 2. Baseline characteristics of patients who were enrolled in the study. According to their Sex (N=60)

Characteristics	Total	HBsAg +ve	HBsAg -ve	Seroprevalence
	(100%)	n(%)	n(%)	
Male	30	03 (10%)	27 (90%)	10%
Female	30	01 (3.33%)	29 (96.33%)	3.33%

Characteristics	Total (100%)	HBsAg +ve n(%)	HBsAg -ve n(%)	Seroprevalence
No formal education	08	01 (12.5%)	07 (87.5%)	12.5%
Primary	25	02 (8%)	23 (92%)	8%
Secondary	17	01 (5.88%)	16 (94.12%)	5.88%
College/ University	10	00 (0%)	10 (100%)	00%

Table 4. Baseline characteristics of patients who were enrolled in the study. According to their Occupation and Employment status (N=60)

Characteristics	Total	HBsAg +ve n(%)	HBsAg -ve n(%)	Seroprevalence
Employed	26	01 (3.84%)	25 (96.16%)	3.84%
Unemployed	09	01 (11.11%)	08 (88.89%)	11.11%
Student	13	01 (7.69%)	12 (92.31%)	7.69%
Housewife	12	01 (8.33%)	11 (91.67%)	8.33%
Others	00	00 (00%)	00 (00%)	00%

Table 5. Baseline characteristics of patients who were enrolled in the study. According to their residence either rural or urban (N=60)

Characteristics	Total	HBsAg +ve	HBsAg -ve	Seroprevalence
	(100%)	n(%)	n(%)	
Rural	47	03 (6.83%)	44 (93.17%)	6.83%
Urban	13	01 (7.69%)	12 (92.31%)	7.69%

Table 6. Seroprevalence of HBV infection among patients attending Okayama Friendship Rural Hospital, Bhaluka, Mymensingh

Characteristics	Total	HBsAg +ve	HBsAg -ve	Seroprevalence of
	Patients enrolled			HBsAg
Total	60	04 (6.66%)	56 (93.33%)	6.66%

noticeable difference was as an increased level of education showed lower seroprevalence of HBsAg.

However, there were no significant differences between those who tested positive and those who tested negative to HBsAg with respect to residence status whether urban or rural.

DISCUSSION

This study has found that the seroprevalence of HBsAg among the patients at Okayama Friendship Rural Hospital, Bhaluka, Mymensingh was 6.6%.

This level of seroprevalence is in agreement with overall prevalence rate 2-8% given by WHO.

WHO defines low prevalence to be <2%, moderate prevalence as 2-8%, and high prevalence as >8% HBsAg positivity. The WHO therefore recommends universal immunization of all infants to be adopted by all countries irrespective of HBsAg prevalence (WHO 2002).

Despite the finding of a relatively stable prevalence of HBsAg as found in this study, it is important to note that there is great chance of increasing seroprevalence among Bangladeshi people due greater human mobility and human interaction between different parts of the country or even different parts of the world. Furthermore, industrialization means many people are living and working in a small area and thereby risk of HBV spreading through sexual contact or by other modes increases substantially.

Study Limitations

This study was limited by the fact that it is a clinic based study and that patients attending the Okayama Friendship Rural Hospital, Bhaluka, Mymensingh are a select population of a specific region mostly from Mymensingh. Hence the results can't be generalized for the whole country. Furthermore, all the patients attending at Okayama Friendship Rural Hospital, Bhaluka, Mymensingh did not give their consent to participate at this study which could also affect the generalization of findings. However, the findings of this study have adequately shed light into the problem of hepatitis B infection among patients at Friendship Okayama Rural Hospital, Bhaluka, Mymensingh.

CONCLUSION AND RECOMMENDATIONS

In conclusion, this study has found that the seroprevalence of HBV infection among patients at Okayama Friendship Rural Hospital, Bhaluka, Mymensingh was 6.6%, which is of moderate intensity, and hence it is suggestive of the need to adopt the WHO recommendations in our set up.

It is recommended that further larger studies be performed to support the findings, since the calculated sample size was based on a higher prevalence figure than the level found in the study. This finding would suggest for the introduction of routine screening for high risk groups for HBV (e.g. Medical and Health Personnel, Frequent Blood Transfusion Receiver, Sex workers, Drug Abuser etc) and vaccination to all people especially young children so as to reduce and prevent the spread of infection. However more data is required from larger studies to support the findings so that ultimately this can be recommended as a policy.

REFERENCES

- Ahmed SD, Cuevas LE, Brabin BJ, Kazembe P, Broadhead R, Verhoeff FH (1998). Seroprevalence of hepatitis B and C and HIV in Malawian pregnant women. J Infect. 1998 Nov;37(3):248-51.
- Akani CI, Ojule AC, Opurum HC, Ejilemele AA (2005). Sero-prevalence of hepatitis B surface antigen (HBsAg) in pregnant women in Port Harcourt, Nigeria. Niger Postgrad Med J. 2005 Dec; 12(4):266-70.
- Alexander JM, Ramus R, Jackson G, Sercely B, Wendel GD, Jr. Risk of hepatitis B transmission after amniocentesis in chronic hepatitis B carriers. Infect Dis Obstet Gynecol. 1999;7(6):283-6.
- Bai H, Zhang L, Ma L, Dou XG, Feng GH, Zhao GZ (2007). Relationship of hepatitis B virus infection of placental barrier and hepatitis B virus intra-uterine transmission mechanism. World J Gastroenterol. 2007 Jul 14;13(26):3625-30.
- Bello Corredor M, Rodriguez Lay Lde L, Delgado Gonzalez G, Diaz Gonzalez M, Montalvo Villar MC, Gutierrez Moreno A (2000-2002). [Surveillance in children of mothers positive to hepatitis B surface antigen, 2000-2002]. Rev Cubana Med Trop. 2004 Jan- Apr;56(1):31-4.
- Bwogi J, Braka F, Makumbi I, Mishra V, Bakamutumaho B, Nanyunja M (2009). Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey. Afr Health Sci. 2009 Jun;9(2):98-108.
- Caldwell CW and Barret JT (1977). Enzyme linked Immunoassay for Hepatitis B and its comparison to other methods. Clin Chem Acta. 1977;81:305.
- Chakravarti A, Rawat D, Jain M (2005). A study on the perinatal transmission of the hepatitis B virus. Indian J Med Microbiol. 2005 Apr;23(2):128-30.
- Cunninghan F, Leveno K, SL B (2005). editors. Williams Obstetrics 22 ed: Mcgraw-hill, :2005.
- Elsheikh RM, Daak AA, Elsheikh MA, Karsany MS, Adam I (2007). Hepatitis B virus and hepatitis C virus in pregnant Sudanese women. Virol J. 2007;4:104.
- Ferreira RC, Rodrigues FP, Teles SA, Lopes CL, Motta-Castro AR, Novais AC (2009). Prevalence of hepatitis B virus and risk factors in Brazilian non-injecting drug users. J Med Virol. 2009 Apr;81(4):602-9.
- Gambarin-Gelwan M (2007). Hepatitis B in pregnancy. Clin Liver Dis. 2007 Nov;11(4):945-63, x.
- Hasslett C, Chilvers E, Hunter J (1999). editors. Davidson's Principles and Practice of MEDICINE, 18 ed: Churchill Livingstone 1999.
- Haukenes G SJ, Mbena E, Rustad S (1987). Hepatitis B virus markers in the population of Das-es-salaam, Tanzania. J Infct 1987;15:183-8.
- Hill JB, Sheffield JS, Kim MJ, Alexander JM, Sercely B, Wendel GD (2002). Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol. 2002 Jun;99(6):1049-52. Jun;78(6):730-3.
- Kasper D, Braunwald E, Fauci A (2005). editors. Harrison's Principles of Internal
- Kibassa CJ, Msengi AE. Determination of vertical transmission of hepatitis B virus in Dar es Salaam. Tanzania Medical Journal. 2004;19:21-5.

- Lau WY, Leung WT, Ho S, Lam SK, Li CY, Johnson PJ, (1995). Hepatocellular carcinoma during pregnancy and its comparison with other pregnancy-associated malignancies. Cancer. 1995 Jun 1;75(11):2669-76.
- Lin HH, Chen PJ, Chen DS, Sung JL, Yang KH, Young YC (1989). Postpartum subsidence of hepatitis B viral replication in HBeAg-positive carrier mothers. J Med Virol. 1989 Sep;29(1):1-6.
- Matee MI, Lyamuya E (2008). Seroprevalence of human immunodeficiency, hepatitis B and C viruses and syphilis infections among blood donors at Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health. 2008;6:21.
- Medicine, 16 ed: The Mc Graw-Hill; 2005.
- Menendez C, Sanchez-Tapias JM, Kahigwa E, Mshinda H, Costa J, Vidal J, (1999). Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. J Med Virol. 1999 Jul;58(3):215-20.
- Metodi J, Aboud S, Mpembeni R, Munubhi E (2010). Immunity to hepatitis B vaccine in children under five years attending reproductive and child health clinic in Dar es Salaam, Tanzania. Ann Trop Paediatr. 2010;(in press).
- Ministry of Health and Social Welfare (2006). Guidelines on the clinical use of blood and blood products. 2006.
- Ministry of Health and Social Welfare (2007). Expanded Programme on immunization 2006- 2010, Tanzania. Dar-es-salaam, Tanzania:Govement press,2007;2 edition, 5-7.
- Mugusi SF, Janabi M, Francis JM, Aboud S, Bakari M, Aris EA, Swai ABM, Mugusi FM, Pallangyo K, Sandstrom E (2010). Effect of Improved access to Antiretroviral Therapy on Clinical Characteristics of patients enrolled in the HIV care and treatment clinics at Muhimbili National Hospital (MNH) (2010). Dar es Salaam, Tanzania. BMC Public Health. 2010;10:291.
- NACP (2009). HIV/AIDS/STI Surveillance Report. July 2009.
- Nagu TJ, Bakari M, Matee MI. Hepatitis A (2008). B and C viral coinfections among HIV infected adults presenting for care and treatment at Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health. 2008;8(416).
- Obi SN, Onah HE, Ezugwu FO (2006). Risk factors for hepatitis B infection during pregnancy in a Nigerian obstetric population. J Obstet Gynaecol. 2006 Nov;26(8):770-2.
- Okoth F, Mbuthia J, Gatheru Z, Murila F, Kanyingi F, Mugo F (2006). Seroprevalence of hepatitis B markers in pregnant women in Kenya. East Afr Med J. 2006Sep;8 3(9):485-93.
- Santiago-Munoz P, Roberts S, Sheffield J, McElwee B, Wendel GD (2005). Jr. Prevalence of hepatitis B and C in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol. 2005 Sep;193(3 Pt 2):1270-3.
- Shao JF, Haukenes G, Yangi E, Vollset SE (1993). Association of hepatitis B and human immunodeficiency virus infections in Tanzanian population groups. Eur J Clin Microbiol Infect Dis. 1993 Jan;12(1):62-4.
- Simpore J, Savadogo A, Ilboudo D, Nadambega MC, Esposito M, Yara J (2006). Toxoplasma gondii, HCV, and HBV seroprevalence and coinfection among HIVpositive and -negative pregnant women in Burkina Faso. J Med Virol. 2006
- Soderstrom A, Norkrans G, Lindh M (2003). Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis. 2003;35(11-12):814-9.
- Su GG, Pan KH, Zhao NF, Fang SH, Yang DH, Zhou Y (2004). Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol. 2004 Mar 15;10(6):910-2.
- Towers CV, Asrat T, Rumney P (2001). The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood. Am J Obstet Gynecol. 2001 Jun;184(7):1514-8; discussion 8-20.

- Tse KY, Ho LF, Lao T (2005). The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study. J Hepatol. 2005 Nov;43(5):771-5.
- UNAIDS, UNAIDS report on the global AIDS epidemic (2010).
- UNAIDS. UNAIDS Report on the global AIDS Epidemic. (2010).
- Vallejo F, Toro C, de la Fuente L, Brugal MT, Soriano V, Silva TC (2008). Prevalence of and risk factors for hepatitis B virus infection among street-recruited young injection and non-injection heroin users in Barcelona, Madrid and Seville. Eur Addict Res. 2008;14(3):116-24.
- W.Levinson EJ (1998). editor. Medical Microbiology and Immunology; 1998.

WHO/CDS/CSR/LYO/2002.2: Hepatitis B

- Xu DZ, Yan YP, Choi BC, Xu JQ, Men K, Zhang JX (2002). Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study. J Med Virol. 2002 May;67(1):20-6.
- Yang YB, Li XM, Shi ZJ, Ma L (2004). Pregnant woman with fulminant hepatic failure caused by hepatitis B virus infection: a case report. World J Gastroenterol. 2004 Aug 1;10(15):2305-6.